Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Second-generation antipsychotics
9 evidence topics · 8 sources
FDA-approved indications of quetiapine extended release
CANMAT guideline: quetiapine XR as second-line monotherapy
“Quetiapine XR: There is good evidence for the efficacy of quetiapine XR for the management of GAD (Level 1)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, quetiapine was associated with more weight gain and sedation, and higher dropout rates due to adverse events compared with placebo or antidepressants” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to tolerability and long-term safety concerns with atypical antipsychotics, this treatment is recommended as a second-line option for patients who cannot be provided antidepressants or benzodiazepines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CANMAT guideline: adjunctive antipsychotics as third-line therapy
“Third-line adjunctive therapies: A meta-analysis of five RCTs of adjunctive atypical antipsychotics found no significant improvement in response rates but higher discontinuation rates versus placebo in patients with refractory GAD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because of the limited evidence for efficacy and their potential for weight gain and metabolic side effects, atypical antipsychotics should be reserved for highly treatment-refractory cases of GAD, and other than quetiapine XR, used only as an adjunctive treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NICE guideline: antipsychotics in primary care
BAP guideline: reserved for nonresponse to other interventions
AAFP review: effectiveness and augmentation
Meta-analysis of quetiapine randomized trials
“A total of 2,248 randomized participants in three RCTs were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Unfortunately, the response and the remission rates in only 50 and 150 mg/day of quetiapine-XR (extended-release) were better than those of the placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The rates of pooled overall discontinuation and discontinuation due to adverse events of quetiapine-XR were greater than placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the pooled discontinuation rate due to adverse events of the quetiapine-treated group being significantly higher than that of the placebo-treated group, with RR (95% CI) of 3.18 (2.52, 4.00), I2=0%, it suggests that quetiapine is less tolerable than placebo in the treatment of GAD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the evidence included in this meta-analysis, the significant adverse events consist of somnolence, sexual dysfunction, and extrapyramidal symptoms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis: effect size and tolerability of quetiapine
Fixed-dose trial of quetiapine XR
“Among patients randomized to fixed-dose treatment (quetiapine XR: 50 mg/day, n=234; 150 mg/d, n=241; 300 mg/d, n=241) or placebo (n=235) quetiapine was statistically superior to placebo except at the 300 mg/day dose, wherein side effects were significantly greater” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote